HC Wainwright Has Bearish Forecast for BEAM FY2025 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Stock analysts at HC Wainwright reduced their FY2025 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, November 5th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($4.22) per share for the year, down from their prior estimate of ($3.78). HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q4 2025 earnings at ($0.90) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($3.53) EPS, FY2027 earnings at ($3.24) EPS, FY2028 earnings at ($2.11) EPS and FY2029 earnings at ($1.66) EPS.

Several other research firms have also issued reports on BEAM. JPMorgan Chase & Co. dropped their price objective on Beam Therapeutics from $48.00 to $46.00 and set an “overweight” rating for the company in a research note on Thursday, October 9th. Barclays dropped their price target on Beam Therapeutics from $25.00 to $21.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 6th. Wall Street Zen upgraded shares of Beam Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Jefferies Financial Group assumed coverage on shares of Beam Therapeutics in a research report on Thursday, October 9th. They set a “buy” rating and a $41.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Beam Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $46.55.

Beam Therapeutics Price Performance

Shares of NASDAQ:BEAM opened at $23.15 on Friday. The firm has a fifty day moving average price of $23.87 and a two-hundred day moving average price of $20.23. The company has a market cap of $2.35 billion, a price-to-earnings ratio of -5.23 and a beta of 2.40. Beam Therapeutics has a one year low of $13.52 and a one year high of $35.25.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.12). Beam Therapeutics had a negative net margin of 744.41% and a negative return on equity of 42.86%. The firm had revenue of $9.70 million for the quarter, compared to analysts’ expectations of $12.83 million. During the same period in the prior year, the firm posted ($1.17) EPS. Beam Therapeutics’s revenue was down 32.2% on a year-over-year basis.

Institutional Investors Weigh In On Beam Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BEAM. Amalgamated Bank lifted its position in Beam Therapeutics by 20.4% during the first quarter. Amalgamated Bank now owns 3,153 shares of the company’s stock valued at $62,000 after buying an additional 534 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Beam Therapeutics by 14.6% during the first quarter. Teacher Retirement System of Texas now owns 23,794 shares of the company’s stock valued at $465,000 after purchasing an additional 3,027 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Beam Therapeutics by 14.8% during the first quarter. Bank of New York Mellon Corp now owns 318,026 shares of the company’s stock valued at $6,211,000 after purchasing an additional 41,109 shares during the last quarter. Concurrent Investment Advisors LLC bought a new stake in shares of Beam Therapeutics in the 1st quarter worth approximately $371,000. Finally, Arizona State Retirement System grew its stake in shares of Beam Therapeutics by 25.6% in the 1st quarter. Arizona State Retirement System now owns 25,534 shares of the company’s stock worth $499,000 after buying an additional 5,197 shares during the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.